Two biotech stocks worth watching who both own discovery platforms in addition to their trials are Dimerix (DXB) and Proteomics (PIQ).
Dimerix in particular is in phase 2 with interim results due soon plus final results due mid-year. Currently competing with Retrophin (NASDAQ) who has just completed phase 2 in a similar trial, but Retrophin are yet to discuss the forward plan with the FDA (unlike Dimerix who have met with the FDA).
2017 should be a big year for both these stocks. Fingers crossed for a biotech boom too which should see some stellar returns for outperforming stocks.
- Forums
- Commodities
- Biotech 2017
Biotech 2017, page-14
- There are more pages in this discussion • 62 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
SS1
SUN SILVER LIMITED
Gerard O’Donovan, Executive Director
Gerard O’Donovan
Executive Director
SPONSORED BY The Market Online